11 completed, 5 recruiting. 16 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 11, Recruiting 5 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Rejection, Psychology: new trials by email Literature Review of Rejection, Psychology trials Research Report on Rejection, Psychology
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases | Phase 3 | Recruiting | Hannover Medical School | 150 | 2026-08-19 | 2026-10-05 |
| A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients Methylprednisolone, Prednisone - Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas | Phase 3 | Recruiting | University of Sydney | 540 | 2026-03-13 | 2026-08-31 |
| Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection | Phase 2 / Phase 3 | Recruiting | Columbia University | 150 | 2025-09-12 | 2026-10-02 |
| Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies Rabbit Anti thymocyte globulin (rATG), Basiliximab - Renal Transplant Rejection, Induction Therapy | Phase 3 | Recruiting | University Hospital, Tours | 244 | 2023-11-07 | 2026-06-18 |
| A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification - BK Viremia, Kidney Transplant Infection | Phase 3 | Recruiting | The University of Queensland | 280 | 2023-08-18 | 2026-06-08 |
| Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Liposomal Cyclosporine A, standard of care - Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant | Phase 3 | Completed | Zambon SpA | 62 | 2019-03-26 | 2025-10-27 |
| Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) Liposomal Cyclosporine A, Standard of Care - Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant | Phase 3 | Completed | Zambon SpA | 169 | 2019-03-26 | 2026-02-10 |
| Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Everolimus, Tacrolimus, Mycophenolate Mofetil - Pediatric Heart Transplantation, Immunosuppression | Phase 3 | Completed | Boston Children's Hospital | 211 | 2018-01-29 | 2026-07-31 |
| 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients Everolimus, Tacrolimus, Cyclosporin A - Kidney Transplantation, Renal Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 612 | 2012-12-27 | 2017-05-01 |
| Donor Simvastatin Treatment in Organ Transplantation Simvastatin 80mg, Control Rx - Heart Failure, Respiratory Failure | Phase 2 / Phase 3 | Completed | Helsinki University Central Hospital | 84 | 2010-06-01 | 2017-09-19 |
| Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch Thymoglobulin, Daclizumab, Plasmapheresis - Kidney Failure, Chronic | Phase 3 | Completed | Johns Hopkins University | 56 | 2007-01-01 | 2018-01-18 |
| Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant FTY720 - Kidney Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 2005-01-01 | 2017-06-07 | |
| Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant placebo, basiliximab - COPD, Emphysema | Phase 3 | Completed | University Health Network, Toronto | 22 | 2004-05-01 | 2017-05-04 |
| Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation FTY720 - Kidney Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 140 | 2004-04-01 | 2016-11-18 |
| Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant FTY 720 - Kidney Transplantation | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 255 | 2003-11-01 | 2017-02-23 |
| Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids - Kidney Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 696 | 2003-05-07 | 2017-08-22 |
Bronchiolitis Obliterans (2) · Emphysema (1) · Graft vs Host Disease (1) · Heart Failure (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Liver Diseases (1) · Liver Failure (1) · Pulmonary Disease, Chronic Obstructive (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1) · Reperfusion Injury (1) · Respiratory Insufficiency (1)
Behavior (16) · Social Behavior (16) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Respiratory Tract Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Chronic Disease (3) · Disease Attributes (3) · Kidney Diseases (3) · Lung Diseases (3) · Lung Diseases, Obstructive (3)
Fingolimod Hydrochloride (4) · Mycophenolic Acid (4) · Tacrolimus (4) · Basiliximab (3) · Everolimus (3) · Adrenal Cortex Hormones (2) · Cyclosporine (2) · Prednisone (2) · Standard of Care (2) · Antilymphocyte Serum (1) · Daclizumab (1) · Dexamethasone (1) · Immunoglobulins, Intravenous (1) · Methylprednisolone (1) · Plasmapheresis (1)
Novartis Pharmaceuticals (5) · Zambon SpA (2) · Boston Children's Hospital (1) · Columbia University (1) · Hannover Medical School (1) · Helsinki University Central Hospital (1) · Johns Hopkins University (1) · The University of Queensland (1) · University Health Network, Toronto (1) · University Hospital, Tours (1) · University of Sydney (1)
United States (7) · France (4) · Germany (4) · Australia (2) · Belgium (2) · Canada (2) · Israel (2) · Spain (2) · United Kingdom (2) · Austria (1) · Denmark (1) · Finland (1) · New Zealand (1)
Paola Castellani, MD (2) · Cecilia Chaparro, MD (1) · Christopher E Simpkins, M.D. (1) · Christopher S Almond, MD, MPH (1) · Germaine Wong, PhD, FRACP (1) · Germaine Wong, Professor (1) · Julie Ho, FRCPC (1) · Karl B Lemstrom, MD, PhD (1) · Kevin P Daly, MD (1) · Lynn A Sleeper, ScD (1) · Richard Taubert, Professor (1) · Robert A Montgomery, M.D., Ph.D. (1)
PMID 15940045, PMID 17198261, PMID 17984842, PMID 18195237, PMID 26888217, PMID 30903722, PMID 31352795, PMID 33315277, PMID 38993854, PMID 39352862, PMID 39382091, PMID 40960806
2018 (2), 2025 (1)